4 assets in Gallbladder Adenocarcinoma

Therapeutic assets addressing Gallbladder Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Gallbladder Adenocarcinoma	Georgetown University	P3	BB (66)
Atezolizumab Gallbladder Adenocarcinoma	Georgetown University	P3	B (60)
Durvalumab Gallbladder Adenocarcinoma	University of Southern California	P1	CC (43)
Guadecitabine Gallbladder Adenocarcinoma	University of Southern California	P1	CC (43)